Imatinib, a receptor tyrosine kinase inhibitor, was first used in the treatment of chronic myelogenous leukemia, which is characterized by the constitutive activation of the Bcr-Abl tyrosine kinase [5]. Here, NTRK1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.